BREVICON 21-DAY
Clinical safety rating
cautionComprehensive clinical and safety monograph for BREVICON 21-DAY (BREVICON 21-DAY).
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
| Metabolism | Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass metabolism in gut wall and liver. Norethindrone: metabolized via reduction and conjugation, primarily excreted as glucuronide conjugates. |
| Excretion | Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor). |
| Half-life | Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy. |
| Protein binding | Norethindrone: 61% bound to albumin and SHBG; Ethinyl estradiol: 97-98% bound to albumin, SHBG not involved. |
| Volume of Distribution | Norethindrone: 4-5 L/kg; Ethinyl estradiol: 3-4 L/kg. High Vd indicates extensive tissue distribution, including breast and reproductive tissues. |
| Bioavailability | Oral: Norethindrone ~64% (first-pass metabolism); Ethinyl estradiol ~45% (first-pass metabolism, high interindividual variability). |
| Onset of Action | Oral: 1-2 hours for serum levels to suppress FSH/LH; contraceptive effect requires 7 days of consistent use for full ovulation inhibition. |
| Duration of Action | 24 hours (daily dosing required); contraceptive effect persists with consistent daily use; withdrawal bleeding occurs during placebo days. |
| Molecular Weight | Ethinyl estradiol 296.40 Da; Norethindrone 298.42 Da |
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). No adjustment needed for Child-Pugh class A. |
| Pediatric use | Use not indicated in pediatric patients before menarche. After menarche, dose is same as adult. |
| Geriatric use | Not approved for use in postmenopausal women. No elderly-specific dose adjustments; use not indicated in this population. |
| 1st trimester | Use is contraindicated in pregnancy; estrogen-progestin combinations increase risk of fetal harm including congenital anomalies and should not be used during the first trimester. |
| 2nd trimester | Contraindicated; may cause fetal harm; use is not recommended at any stage of pregnancy. |
| 3rd trimester | Contraindicated; exposure during third trimester may cause adverse effects such as jaundice, fluid retention, and genital abnormalities. |
Clinical note
Comprehensive clinical and safety monograph for BREVICON 21-DAY (BREVICON 21-DAY).
| Placental transfer | Established; the hormones in Brevicon cross the placenta readily as evidenced by fetal exposure linked to adverse outcomes. Estrogen and progestin levels in fetal blood approximate maternal levels. |
| Breastfeeding | Not recommended during breastfeeding; estrogen and progestin may reduce milk production and quality, and small amounts may pass into breast milk potentially affecting the infant. Use alternative contraception methods. |
| Lactation Rating | L5 (Contraindicated, high risk) |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to established risk of fetal harm. First trimester: Exposure associated with cardiovascular defects (e.g., VSD), limb reduction defects, and neural tube defects; risk increases with dose and duration. Second and third trimesters: Potential for fetal adrenal suppression, masculinization of female genitalia (from progestin component), and long-term neurodevelopmental effects. Postmarketing data confirm elevated risk of congenital anomalies. |
| Fetal Monitoring | Monitor pregnancy status (beta-hCG) before initiation; discontinue immediately if pregnancy occurs. Periodic blood pressure monitoring due to estrogen component. Assess for signs of thromboembolism (edema, chest pain, dyspnea). Inadvertent pregnancy: perform ultrasound for fetal anatomy and growth. No routine fetal monitoring required if pregnancy avoided; if exposed, consider fetal echocardiogram and detailed anomaly scan. |
| Fertility Effects | Suppresses ovulation via inhibition of gonadotropins; intended to prevent pregnancy. Upon discontinuation, normal menstrual cycles typically resume within 1-3 months, with no long-term reduction in fertility. Reversible effect. No evidence of permanent impairment. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from oral contraceptive use, especially in women >35 years old and those smoking ≥15 cigarettes/day.
| Serious Effects |
Known or suspected pregnancyBreastfeedingCurrent or history of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism)Cerebrovascular or coronary artery diseaseKnown or suspected estrogen-dependent neoplasia (e.g., breast cancer)Undiagnosed abnormal genital bleedingKnown or suspected carcinoma of the breast or endometriumActive liver disease or impaired liver function (e.g., hepatitis, cirrhosis, tumors)Use of strong CYP3A4 inducers (e.g., rifampin, anticonvulsants) causing reduced contraceptive efficacyHistory of jaundice with pregnancy or previous oral contraceptive useHeavy smoking (≥15 cigarettes/day) in women over 35 yearsKnown hypersensitivity to any component
| Precautions | Increased risk of venous thromboembolism (VTE) and arterial thrombosis, especially in smokers or those with predisposing factors, Elevated risk of cardiovascular events in women with hypertension, diabetes, or hyperlipidemias, Hepatic neoplasia risk with long-term use, Increased risk of gallbladder disease, May cause fluid retention and exacerbate conditions like migraine, seizure disorders, renal impairment |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase ethinylestradiol levels, but not clinically relevant. Avoid excessive alcohol. |
| Clinical Pearls | Brevinor-21 is a combined oral contraceptive containing norethisterone and ethinylestradiol. It suppresses ovulation and alters cervical mucus. Monitor for thromboembolic events; contraindicated in smokers over 35. Breakthrough bleeding may occur, especially in first cycles. Missed pill management: if one pill missed, take it ASAP; if two or more missed, use backup contraception. |
| Patient Advice | Take one pill daily at the same time for 21 days, then 7 pill-free days. · Use backup contraception (e.g., condoms) if you miss pills or start late. · Common side effects: nausea, breast tenderness, mood changes; usually improve. · Seek medical help for severe leg pain, chest pain, or sudden severe headache. · Smoking increases risk of serious cardiovascular side effects. |
Loading safety data…